Ranbaxy's Discovery Unit To Move Into Daiichi Sankyo's Global R&D Structure To Create New Drugs Faster
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Keeping with the "hybrid business model" that it envisioned in taking over India's largest drug maker Ranbaxy in June 2008, Daiichi Sankyo has announced that the New Drug Discovery Research unit of the Indian firm will be transferred to its global R&D structure. The transaction has been approved by India's Department of Scientific and Industrial Research